These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 9059336)

  • 1. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation.
    Vermeulen PB; Gasparini G; Fox SB; Toi M; Martin L; McCulloch P; Pezzella F; Viale G; Weidner N; Harris AL; Dirix LY
    Eur J Cancer; 1996 Dec; 32A(14):2474-84. PubMed ID: 9059336
    [No Abstract]   [Full Text] [Related]  

  • 2. Intra-tumoural microvessel density in human solid tumours.
    Hasan J; Byers R; Jayson GC
    Br J Cancer; 2002 May; 86(10):1566-77. PubMed ID: 12085206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of endothelial activation on fibrinolysis and local proteolysis in tissue repair.
    van Hinsbergh VW
    Ann N Y Acad Sci; 1992 Dec; 667():151-62. PubMed ID: 1285019
    [No Abstract]   [Full Text] [Related]  

  • 4. Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers.
    Duffy MJ
    Biochem Soc Trans; 2002 Apr; 30(2):207-10. PubMed ID: 12023852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: binding, internalization, degradation, and biological effects.
    Bikfalvi A; Sauzeau C; Moukadiri H; Maclouf J; Busso N; Bryckaert M; Plouet J; Tobelem G
    J Cell Physiol; 1991 Oct; 149(1):50-9. PubMed ID: 1719003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor (VEGF) & tumour angiogenesis.
    Moulik S; Chatterjee A
    Indian J Med Res; 2007 Jun; 125(6):715-6. PubMed ID: 17704546
    [No Abstract]   [Full Text] [Related]  

  • 8. [Significance of vascular endothelial growth factor--VEGF--in tumor angiogenesis. Therapeutic possibilities in solid tumors].
    Werther K; Nielsen HJ
    Ugeskr Laeger; 2000 Sep; 162(37):4916-20. PubMed ID: 11002739
    [No Abstract]   [Full Text] [Related]  

  • 9. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours.
    Vermeulen PB; Gasparini G; Fox SB; Colpaert C; Marson LP; Gion M; Beliën JA; de Waal RM; Van Marck E; Magnani E; Weidner N; Harris AL; Dirix LY
    Eur J Cancer; 2002 Aug; 38(12):1564-79. PubMed ID: 12142044
    [No Abstract]   [Full Text] [Related]  

  • 10. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
    Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C
    Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
    Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
    Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
    Morii T; Yabe H; Morioka H; Yamada R; Nakagawa T; Toyama Y
    Anticancer Res; 2000; 20(5A):3031-6. PubMed ID: 11062719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
    Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
    Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review).
    Reuning U; Magdolen V; Wilhelm O; Fischer K; Lutz V; Graeff H; Schmitt M
    Int J Oncol; 1998 Nov; 13(5):893-906. PubMed ID: 9772277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human prostate tumor angiogenesis in nude mice: metalloprotease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells.
    Wilson MJ; Sinha AA
    Anat Rec; 1997 Sep; 249(1):63-73. PubMed ID: 9294650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer.
    Shin VY; Wu WK; Chu KM; Wong HP; Lam EK; Tai EK; Koo MW; Cho CH
    Mol Cancer Res; 2005 Nov; 3(11):607-15. PubMed ID: 16317086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activator inhibitor-1 in cancer research.
    Li S; Wei X; He J; Tian X; Yuan S; Sun L
    Biomed Pharmacother; 2018 Sep; 105():83-94. PubMed ID: 29852393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
    Duffy MJ; Duggan C
    Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis.
    Inoue M; Sawada T; Uchima Y; Kimura K; Nishihara T; Tanaka H; Yashiro M; Yamada N; Ohira M; Hirakawa K
    Oncol Rep; 2005 Dec; 14(6):1445-51. PubMed ID: 16273237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis.
    Ruiter DJ; Ferrier CM; van Muijen GN; Henzen-Logmans SC; Kennedy S; Kramer MD; Nielsen BS; Schmitt M
    Eur J Cancer; 1998 Aug; 34(9):1334-40. PubMed ID: 9849413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.